Medical condition
Fibrosis
Fibrosis is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- nintedanib (OFEV) Antineoplastic and immunomodulating agents (L01)
- mannitol (BRONCHITOL) Respiratory system (R05)
- pirfenidone (ARX-PIRFENIDONE) Antineoplastic and immunomodulating agents (L04)
- resmetirom (REZDIFFRA) Alimentary tract and metabolism (A05)
- deutivacaftor (ALYFTREK)
- colistimethate sodium (COLOBREATHE) Antiinfectives for systemic use (J01)
- levofloxacin (QUINSAIR) Antiinfectives for systemic use (J01)
- entecavir (ENTAC) Antiinfectives for systemic use (J05)
- lamivudine (3TC) Antiinfectives for systemic use (J05)
- ivacaftor (KALYDECO) Respiratory system (R07)
- tobramycin (PFIZER AUSTRALIA PTY LTD) Antiinfectives for systemic use (J01)
- lumacaftor (ORKAMBI) Respiratory system (R07)
Latest Fibrosis news
Lilly’s early JAK data raises myelofibrosis competition question
Eli Lilly reported early positive data for a next-generation JAK inhibitor acquired through Ajax. The readout could position Lilly as a potential future competitor to Incyte’s Jakafi in myelofibrosis.
Oorja Launches New Fibrosis Drugs: Insights from Acceleron Veterans
Oorja, a new biotech startup led by Acceleron veterans, aims to develop innovative fibrosis drugs. This article explores the implications for the pharmaceutical industry.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
Rein Therapeutics LTI-03 Phase 2 Trial Enrolls 8 Patients for Idiopathic Pulmonary Fibrosis Treatment
Rein Therapeutics reports 8 patients enrolled in Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis across US, Australia, and Poland sites.
FDA Approves GeneCorrect: GeneTech's Breakthrough Cystic Fibrosis Therapy
GeneTech's GeneCorrect has received FDA approval, marking a significant advancement in the treatment of cystic fibrosis and improving patient outcomes.
FDA Approves Trikafta for Cystic Fibrosis in Children Ages 2-5
The FDA has approved Trikafta for the treatment of cystic fibrosis in children aged 2 to 5, marking a significant advancement in pediatric care.